Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival

To evaluate the outcomes of pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)] surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). Surgery offers the only chance for cure in PDAC. PVR is oft...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of surgery 2023-06, Vol.277 (6), p.e1291-e1298
Hauptverfasser: Hackert, Thilo, Klaiber, Ulla, Hinz, Ulf, Strunk, Susanne, Loos, Martin, Strobel, Oliver, Berchtold, Christoph, Kulu, Yakup, Mehrabi, Arianeb, Müller-Stich, Beat P., Schneider, Martin, Büchler, Markus W.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e1298
container_issue 6
container_start_page e1291
container_title Annals of surgery
container_volume 277
creator Hackert, Thilo
Klaiber, Ulla
Hinz, Ulf
Strunk, Susanne
Loos, Martin
Strobel, Oliver
Berchtold, Christoph
Kulu, Yakup
Mehrabi, Arianeb
Müller-Stich, Beat P.
Schneider, Martin
Büchler, Markus W.
description To evaluate the outcomes of pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)] surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). Surgery offers the only chance for cure in PDAC. PVR is often performed for borderline or locally advanced tumors. Consecutive patients with PDAC operated between January 2006 and January 2018 were included. Clinicopathologic characteristics and outcomes were analyzed and tested for survival prediction. Of 2265 PDAC resections, 1571 (69.4%) were standard resections and 694 (30.6%) were resections with PVR, including 149 (21.5%) tangential resections with venorrhaphy (ISGPS type 1), 21 (3.0%) resections with patch reconstruction (type 2), 491 (70.7%) end-to-end anastomoses (type 3), and 33 (4.8%) resections with graft interposition (type 4). The 90-day mortality rate was 2.6% after standard resection and 6.3% after resection with PVR ( P 1 mm) resection resulted in 23.3 months of median survival. This is the largest single-center, comparative cohort study of PVR in PDAC surgery, showing that postoperative morbidity correlates with the reconstruction type. When radical resection is achieved, thrombosis risk is outweighed by beneficial overall survival times of nearly 2 years.
doi_str_mv 10.1097/SLA.0000000000005444
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2685445658</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2685445658</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3528-592495ffd176ab29808c6933f09be5196dfb041dc9f8f48ea08af7a4b2d61b253</originalsourceid><addsrcrecordid>eNpdkF1P5CAUholZo7PqPzAbLvemCi204J0ZdXeTSTTjx21D6cFhpUWhHTP_XiYzfkRu4JDzPufkQeiYkhNKZHV6Ozs_IV8OZ4ztoAnlucgoZeQHmqTfImOyyPfRzxj_E0KZINUe2i94JYtCsAla3PgwKIcfwPZ4DhH0YH2PU3Gjeh1ADVbjaXpCwLdjeISwOsNzG5-wN_huEXzX-GgjVn2L56q1Wjk7rPAFDBA628M6tLRL5Q7RrlEuwtH2PkD3V5d307_Z7PrPv-n5LNPFenMucya5MS2tStXkUhChy7SrIbIBTmXZmoYw2mpphGECFBHKVIo1eVvSJufFAfq94T4H_zJCHOrORg3OqR78GOu8FMkUL7lIrWzTqoOPMYCpn4PtVFjVlNRrx3VyXH93nGK_thPGpoP2I_Qu9ZP76l3SEJ_c-AqhXoByw2LDS-MzKbfUbE0WxRvK4obq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685445658</pqid></control><display><type>article</type><title>Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival</title><source>MEDLINE</source><source>Journals@Ovid Ovid Autoload</source><source>PubMed Central</source><creator>Hackert, Thilo ; Klaiber, Ulla ; Hinz, Ulf ; Strunk, Susanne ; Loos, Martin ; Strobel, Oliver ; Berchtold, Christoph ; Kulu, Yakup ; Mehrabi, Arianeb ; Müller-Stich, Beat P. ; Schneider, Martin ; Büchler, Markus W.</creator><creatorcontrib>Hackert, Thilo ; Klaiber, Ulla ; Hinz, Ulf ; Strunk, Susanne ; Loos, Martin ; Strobel, Oliver ; Berchtold, Christoph ; Kulu, Yakup ; Mehrabi, Arianeb ; Müller-Stich, Beat P. ; Schneider, Martin ; Büchler, Markus W.</creatorcontrib><description>To evaluate the outcomes of pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)] surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). Surgery offers the only chance for cure in PDAC. PVR is often performed for borderline or locally advanced tumors. Consecutive patients with PDAC operated between January 2006 and January 2018 were included. Clinicopathologic characteristics and outcomes were analyzed and tested for survival prediction. Of 2265 PDAC resections, 1571 (69.4%) were standard resections and 694 (30.6%) were resections with PVR, including 149 (21.5%) tangential resections with venorrhaphy (ISGPS type 1), 21 (3.0%) resections with patch reconstruction (type 2), 491 (70.7%) end-to-end anastomoses (type 3), and 33 (4.8%) resections with graft interposition (type 4). The 90-day mortality rate was 2.6% after standard resection and 6.3% after resection with PVR ( P &lt;0.0001). Postoperative portal vein thrombosis and pancreas-specific surgical complications most frequently occurred after PVR with graft interposition (21.2% and 48.5%, respectively). In multivariable analysis, age 70 years and above, ASA stages 3/4, increased preoperative serum carbohydrate antigen 19-9, neoadjuvant treatment, total pancreatectomy, PVR, higher UICC stage, and R+ resections were significant negative prognostic factors for overall survival. Radical R0 (&gt;1 mm) resection resulted in 23.3 months of median survival. This is the largest single-center, comparative cohort study of PVR in PDAC surgery, showing that postoperative morbidity correlates with the reconstruction type. When radical resection is achieved, thrombosis risk is outweighed by beneficial overall survival times of nearly 2 years.</description><identifier>ISSN: 0003-4932</identifier><identifier>EISSN: 1528-1140</identifier><identifier>DOI: 10.1097/SLA.0000000000005444</identifier><identifier>PMID: 35793384</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Aged ; Carcinoma, Pancreatic Ductal ; Cohort Studies ; Humans ; Pancreas - surgery ; Pancreatectomy - methods ; Pancreatic Neoplasms ; Pancreaticoduodenectomy - methods ; Portal Vein - pathology ; Portal Vein - surgery ; Retrospective Studies ; Venous Thrombosis - pathology</subject><ispartof>Annals of surgery, 2023-06, Vol.277 (6), p.e1291-e1298</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3528-592495ffd176ab29808c6933f09be5196dfb041dc9f8f48ea08af7a4b2d61b253</citedby><cites>FETCH-LOGICAL-c3528-592495ffd176ab29808c6933f09be5196dfb041dc9f8f48ea08af7a4b2d61b253</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35793384$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hackert, Thilo</creatorcontrib><creatorcontrib>Klaiber, Ulla</creatorcontrib><creatorcontrib>Hinz, Ulf</creatorcontrib><creatorcontrib>Strunk, Susanne</creatorcontrib><creatorcontrib>Loos, Martin</creatorcontrib><creatorcontrib>Strobel, Oliver</creatorcontrib><creatorcontrib>Berchtold, Christoph</creatorcontrib><creatorcontrib>Kulu, Yakup</creatorcontrib><creatorcontrib>Mehrabi, Arianeb</creatorcontrib><creatorcontrib>Müller-Stich, Beat P.</creatorcontrib><creatorcontrib>Schneider, Martin</creatorcontrib><creatorcontrib>Büchler, Markus W.</creatorcontrib><title>Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival</title><title>Annals of surgery</title><addtitle>Ann Surg</addtitle><description>To evaluate the outcomes of pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)] surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). Surgery offers the only chance for cure in PDAC. PVR is often performed for borderline or locally advanced tumors. Consecutive patients with PDAC operated between January 2006 and January 2018 were included. Clinicopathologic characteristics and outcomes were analyzed and tested for survival prediction. Of 2265 PDAC resections, 1571 (69.4%) were standard resections and 694 (30.6%) were resections with PVR, including 149 (21.5%) tangential resections with venorrhaphy (ISGPS type 1), 21 (3.0%) resections with patch reconstruction (type 2), 491 (70.7%) end-to-end anastomoses (type 3), and 33 (4.8%) resections with graft interposition (type 4). The 90-day mortality rate was 2.6% after standard resection and 6.3% after resection with PVR ( P &lt;0.0001). Postoperative portal vein thrombosis and pancreas-specific surgical complications most frequently occurred after PVR with graft interposition (21.2% and 48.5%, respectively). In multivariable analysis, age 70 years and above, ASA stages 3/4, increased preoperative serum carbohydrate antigen 19-9, neoadjuvant treatment, total pancreatectomy, PVR, higher UICC stage, and R+ resections were significant negative prognostic factors for overall survival. Radical R0 (&gt;1 mm) resection resulted in 23.3 months of median survival. This is the largest single-center, comparative cohort study of PVR in PDAC surgery, showing that postoperative morbidity correlates with the reconstruction type. When radical resection is achieved, thrombosis risk is outweighed by beneficial overall survival times of nearly 2 years.</description><subject>Aged</subject><subject>Carcinoma, Pancreatic Ductal</subject><subject>Cohort Studies</subject><subject>Humans</subject><subject>Pancreas - surgery</subject><subject>Pancreatectomy - methods</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreaticoduodenectomy - methods</subject><subject>Portal Vein - pathology</subject><subject>Portal Vein - surgery</subject><subject>Retrospective Studies</subject><subject>Venous Thrombosis - pathology</subject><issn>0003-4932</issn><issn>1528-1140</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkF1P5CAUholZo7PqPzAbLvemCi204J0ZdXeTSTTjx21D6cFhpUWhHTP_XiYzfkRu4JDzPufkQeiYkhNKZHV6Ozs_IV8OZ4ztoAnlucgoZeQHmqTfImOyyPfRzxj_E0KZINUe2i94JYtCsAla3PgwKIcfwPZ4DhH0YH2PU3Gjeh1ADVbjaXpCwLdjeISwOsNzG5-wN_huEXzX-GgjVn2L56q1Wjk7rPAFDBA628M6tLRL5Q7RrlEuwtH2PkD3V5d307_Z7PrPv-n5LNPFenMucya5MS2tStXkUhChy7SrIbIBTmXZmoYw2mpphGECFBHKVIo1eVvSJufFAfq94T4H_zJCHOrORg3OqR78GOu8FMkUL7lIrWzTqoOPMYCpn4PtVFjVlNRrx3VyXH93nGK_thPGpoP2I_Qu9ZP76l3SEJ_c-AqhXoByw2LDS-MzKbfUbE0WxRvK4obq</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Hackert, Thilo</creator><creator>Klaiber, Ulla</creator><creator>Hinz, Ulf</creator><creator>Strunk, Susanne</creator><creator>Loos, Martin</creator><creator>Strobel, Oliver</creator><creator>Berchtold, Christoph</creator><creator>Kulu, Yakup</creator><creator>Mehrabi, Arianeb</creator><creator>Müller-Stich, Beat P.</creator><creator>Schneider, Martin</creator><creator>Büchler, Markus W.</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20230601</creationdate><title>Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival</title><author>Hackert, Thilo ; Klaiber, Ulla ; Hinz, Ulf ; Strunk, Susanne ; Loos, Martin ; Strobel, Oliver ; Berchtold, Christoph ; Kulu, Yakup ; Mehrabi, Arianeb ; Müller-Stich, Beat P. ; Schneider, Martin ; Büchler, Markus W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3528-592495ffd176ab29808c6933f09be5196dfb041dc9f8f48ea08af7a4b2d61b253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Aged</topic><topic>Carcinoma, Pancreatic Ductal</topic><topic>Cohort Studies</topic><topic>Humans</topic><topic>Pancreas - surgery</topic><topic>Pancreatectomy - methods</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreaticoduodenectomy - methods</topic><topic>Portal Vein - pathology</topic><topic>Portal Vein - surgery</topic><topic>Retrospective Studies</topic><topic>Venous Thrombosis - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hackert, Thilo</creatorcontrib><creatorcontrib>Klaiber, Ulla</creatorcontrib><creatorcontrib>Hinz, Ulf</creatorcontrib><creatorcontrib>Strunk, Susanne</creatorcontrib><creatorcontrib>Loos, Martin</creatorcontrib><creatorcontrib>Strobel, Oliver</creatorcontrib><creatorcontrib>Berchtold, Christoph</creatorcontrib><creatorcontrib>Kulu, Yakup</creatorcontrib><creatorcontrib>Mehrabi, Arianeb</creatorcontrib><creatorcontrib>Müller-Stich, Beat P.</creatorcontrib><creatorcontrib>Schneider, Martin</creatorcontrib><creatorcontrib>Büchler, Markus W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hackert, Thilo</au><au>Klaiber, Ulla</au><au>Hinz, Ulf</au><au>Strunk, Susanne</au><au>Loos, Martin</au><au>Strobel, Oliver</au><au>Berchtold, Christoph</au><au>Kulu, Yakup</au><au>Mehrabi, Arianeb</au><au>Müller-Stich, Beat P.</au><au>Schneider, Martin</au><au>Büchler, Markus W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival</atitle><jtitle>Annals of surgery</jtitle><addtitle>Ann Surg</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>277</volume><issue>6</issue><spage>e1291</spage><epage>e1298</epage><pages>e1291-e1298</pages><issn>0003-4932</issn><eissn>1528-1140</eissn><abstract>To evaluate the outcomes of pancreatic cancer [pancreatic ductal adenocarcinoma (PDAC)] surgery with concomitant portal vein resection (PVR), focusing on the PVR type according to the International Study Group of Pancreatic Surgery (ISGPS). Surgery offers the only chance for cure in PDAC. PVR is often performed for borderline or locally advanced tumors. Consecutive patients with PDAC operated between January 2006 and January 2018 were included. Clinicopathologic characteristics and outcomes were analyzed and tested for survival prediction. Of 2265 PDAC resections, 1571 (69.4%) were standard resections and 694 (30.6%) were resections with PVR, including 149 (21.5%) tangential resections with venorrhaphy (ISGPS type 1), 21 (3.0%) resections with patch reconstruction (type 2), 491 (70.7%) end-to-end anastomoses (type 3), and 33 (4.8%) resections with graft interposition (type 4). The 90-day mortality rate was 2.6% after standard resection and 6.3% after resection with PVR ( P &lt;0.0001). Postoperative portal vein thrombosis and pancreas-specific surgical complications most frequently occurred after PVR with graft interposition (21.2% and 48.5%, respectively). In multivariable analysis, age 70 years and above, ASA stages 3/4, increased preoperative serum carbohydrate antigen 19-9, neoadjuvant treatment, total pancreatectomy, PVR, higher UICC stage, and R+ resections were significant negative prognostic factors for overall survival. Radical R0 (&gt;1 mm) resection resulted in 23.3 months of median survival. This is the largest single-center, comparative cohort study of PVR in PDAC surgery, showing that postoperative morbidity correlates with the reconstruction type. When radical resection is achieved, thrombosis risk is outweighed by beneficial overall survival times of nearly 2 years.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>35793384</pmid><doi>10.1097/SLA.0000000000005444</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4932
ispartof Annals of surgery, 2023-06, Vol.277 (6), p.e1291-e1298
issn 0003-4932
1528-1140
language eng
recordid cdi_proquest_miscellaneous_2685445658
source MEDLINE; Journals@Ovid Ovid Autoload; PubMed Central
subjects Aged
Carcinoma, Pancreatic Ductal
Cohort Studies
Humans
Pancreas - surgery
Pancreatectomy - methods
Pancreatic Neoplasms
Pancreaticoduodenectomy - methods
Portal Vein - pathology
Portal Vein - surgery
Retrospective Studies
Venous Thrombosis - pathology
title Portal Vein Resection in Pancreatic Cancer Surgery: Risk of Thrombosis and Radicality Determine Survival
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T17%3A17%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Portal%20Vein%20Resection%20in%20Pancreatic%20Cancer%20Surgery:%20Risk%20of%20Thrombosis%20and%20Radicality%20Determine%20Survival&rft.jtitle=Annals%20of%20surgery&rft.au=Hackert,%20Thilo&rft.date=2023-06-01&rft.volume=277&rft.issue=6&rft.spage=e1291&rft.epage=e1298&rft.pages=e1291-e1298&rft.issn=0003-4932&rft.eissn=1528-1140&rft_id=info:doi/10.1097/SLA.0000000000005444&rft_dat=%3Cproquest_cross%3E2685445658%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685445658&rft_id=info:pmid/35793384&rfr_iscdi=true